MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12th, 2023.
TELA’s management is scheduled to present at 11:15 am ET on January 12th, 2023. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
Related news for (TELA)
- TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
- TELA Bio Appoints Jeffrey Blizard as President
- TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TELA Bio to Announce First Quarter 2025 Financial Results